trending Market Intelligence /marketintelligence/en/news-insights/trending/udkgXVtNMZ4xvG4US97fSQ2 content esgSubNav
In This List

Abattis Bioceuticals enters into definitive merger agreement with NutriVida


Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap


Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future


Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


Perspectives from China: Chinese M&A in 2022

Abattis Bioceuticals enters into definitive merger agreement with NutriVida

Canada's Abattis Bioceuticals Corp. entered a definitive share exchange agreement with NutriVida.

Vancouver, British Columbia-based Abattis will acquire NutriVida for 58,823,529 common shares at a deemed price of 8.5 Canadian cents per share and C$250,000 in cash.

The companies had signed a nonbinding letter of agreement in December 2018.

NutriVida, which is the operating name of 1157016 B.C. Ltd., is a privately held fertilizer and nutrient company based in Langley, British Columbia.

Abattis Bioceuticals also agreed to pay additional milestone payments of up to C$10 million in shares, based on the achievement of certain revenue targets and permits in several U.S. states.

Upon closing of the acquisition, the Abattis Bioceuticals board will comprise six nominees from the company and one nominee from NutriVida.

Abattis Bioceuticals said the NutriVida deal complements its acquisition of Select Strains Inc., as it works to become a vertically integrated cannabis cultivation company.

The transaction remains subject to due diligence, approval from both the Abattis Bioceuticals and NutriVida boards, as well as other customary conditions.

Abattis Bioceuticals is a life sciences and biotechnology company that aggregates, integrates and invests in cannabis technologies and biotechnology services.